EBV(+) refractory or relapsed non-Hodgkin lymphoma (NHL) patients responded to PD-1 blockade, as opposed to EBV(−) NHL patients [49], and antitumor activity was more evident after PD-1 blockade in EBV(+) DLBCL than in EBV(−) DLBCL cells [50]. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.